Showing 3971-3980 of 4677 results for "".
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM
- Perrigo Company Acquires Cobrek Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130102-perrigo_company_acquires_cobrek_pharmaceuticals_inc/2459651/Perrigo Company signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, Inc. for approximately $45 million on a cash-free and debt-free basis. The merge concludes a four-year collaborative partnership responsi
- Allergan Acquires SkinMedicahttps://practicaldermatology.com/news/20121221-allergan_acquires_skinmedica/2459654/Allergan, Inc. completed the acquisition of SkinMedica, Inc. Under the terms of the agreement, which was first announced on November 16, 2012, Allergan paid approximately $350 million (subject to certain adjustments) for the business, which inclu
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- PreCision Dermatology Adds to Board of Directorshttps://practicaldermatology.com/news/20121211-precision_dermatology_adds_to_board_of_directors/2459660/PreCision Dermatology, Inc. appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice Pr
- AD RescueWear Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/20121204-ad_rescuewear_receives_nea_seal_of_acceptance/2459662/The National Eczema Association Seal of Acceptance was awarded to AD RescueWear for its use by patients with eczema or severe sensitive skin conditions. AD RescueWear manufactures and sells ready-made, wet wrap therapy products for the treatment
- CryoShape Uses Cold to Reduce Scarshttps://practicaldermatology.com/news/20121203-cryoshape_uses_cold_to_reduce_scars/2459667/CryoShape is a patented handheld device for treating keloid and hypertrophic scars. Physicians can destroy deep tissue using an extremely cold probe that is injected directly into the scar. Treating scars with cold freezes them from the inside,
- New Data Show Stelara Effective for Psoriatic Arthritishttps://practicaldermatology.com/news/20121203-new_data_finds_stelara_effective_for_psoriatic_arthritis/2459669/Findings from the PSUMMIT II Phase 3 investigational study showed patients with active psoriatic arthritis receiving Stelara (ustekinumab, Jannsen) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patie
- Jonah Shacknai Honored at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20121203-jonah_shacknai_honored_at_cosmetic_surgery_forum/2459670/Innovators in the field of cosmetic dermatology were honored this past weekend at Cosmetic Surgery Forum, a discussion-based CME symposium held in Las Vegas and now in its fourth year. Jonah Shacknai, Founder of Medicis, was the recipient of the Lifetime Achievement in Dermatology Award. On receivin
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the compa